Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
The USFDA inspectors issued the observations after a product pre-approval inspection of the biologics facility in Bachupally
The inspection closed with zero observations
New Board of Directors and management team at Suven Pharma also appointed
The successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make highquality biosimilar products more accessible and affordable
India is working towards augmenting health infrastructure and have initiated multiple schemes to strengthen health systems and improve health service delivery
The integration and transition of the brands are expected to be completed by June 2022.
The Toradol tablets, 10 mg brand and generic had U.S. sales of approximately US $ 16.8 million MAT for the most recent twelve months ending in March 2022 according to IQVIA
HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)